уп подлежащото онкологично заболяване или цитотоксичната химиотерапия.
In randomised clinical studies in patients with malignancy receiving Neupopeg after cytotoxic chemotherapy, most adverse events were caused by the underlying malignancy or cytotoxic chemotherapy.